Iterum Therapeutics Announces Collaboration with EVERSANA to Support Oral Sulopenem Launch Feb 1, 2021
Iterum Therapeutics Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem Jan 25, 2021
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors Dec 23, 2020
Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority Dec 7, 2020
Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem Nov 30, 2020
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 Oct 19, 2020
